Selective endothelin-1 receptor type A inhibition in subjects undergoing cardiac surgery with preexisting left ventricular dysfunction: Influence on early postoperative hemodynamics.

What Was Tested

Researchers studied Isoxazoles in this randomized controlled trial publication.

A robust release of endothelin-1 with subsequent endothelin-A subtype receptor activation occurs in patients after cardiac surgery requiring cardiopulmonary bypass.

Accordingly, this study tested the hypothesis that a selective endothelin-A subtype receptor antagonist administered perioperatively would favorably affect post-cardiopulmonary bypass hemodynamic profiles in patients with a preexisting poor left ventricular ejection fraction.

Who Took Part

PubMed indexes the participants as middle-aged adults and older adults, both men and women.

Endothelin and hemodynamic measurements were performed at baseline, at separation from cardiopulmonary bypass (time 0), and at 0.5, 6, 12, and 24 hours after cardiopulmonary bypass.

How the Study Was Run

The researchers set it up as a randomized and single-blind study.

Random assignment meant chance, not the researchers, decided who got Isoxazoles and who got the comparison, which limits bias.

In this single-blind Isoxazoles study one party knew the assignments and the other did not.

Infusion of the endothelin-A subtype receptor antagonist/vehicle was performed immediately before separation from cardiopulmonary bypass and again at 12 hours after cardiopulmonary bypass.

What Was Measured

Topics PubMed links to this paper include Cardiopulmonary Bypass, Endothelin A Receptor Antagonists, Hemodynamics, Isoxazoles, Postoperative Complications, Postoperative Period and Risk Factors.

What This Means in Plain Language

The paper is a randomized and single-blind study of Isoxazoles.

Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2010 (The Journal of thoracic and cardiovascular surgery), a journal based in United States.

More context: all human trials.